BACKGROUND: Myeloperoxidase (MPO) concentrations predict adverse clinical outcomes in the setting of acute coronary syndromes and heart failure, but the prognostic role of MPO in stable patients with known atherosclerotic burden is unclear. METHODS: We examined plasma MPO concentrations and their relationship with prevalent significant coronary artery disease (defined as >50% stenosis in any coronary vessel) and incident major adverse cardiovascular events (MACEs), including death, myocardial infarction, and stroke, in a 3-year prospective follow-up study of 1895 patients undergoing elective coronary angiography. RESULTS: The median plasma MPO concentration was 101 pmol/L (interquartile range 68-187 pmol/L). Patients with plasma MPO concentrations >322 pmol/L (14.6% of population) had increased risk of developing future MACEs [hazard ratio (HR) 1.78, 95% CI 1.33-2.37, P < 0.001], and MPO as a single variable predictor of MACE showed an area under the ROC curve of 0.67. After adjusting for traditional cardiac risk factors, creatinine clearance, B-type natriuretic peptide, and high-sensitivity C-reactive protein (hsCRP), increased MPO concentrations remained significantly associated with incident MACEs over the ensuing 3-year period (HR 1.71; 95% CI 1.27-2.30, P < 0.001). In patients with increased hsCRP, MPO ≤322 pmol/L was associated with lower event rates than observed with MPO >322 pmol/L. CONCLUSIONS: Plasma MPO concentrations provide independent prognostic value for the prediction of long-term incident MACEs in a stable, medically managed patient population with coronary artery disease. In individuals with increased hsCRP concentrations, we observed lower risk of incident MACEs when concomitant MPO concentrations were low vs when MPO concentrations were high.
BACKGROUND:Myeloperoxidase (MPO) concentrations predict adverse clinical outcomes in the setting of acute coronary syndromes and heart failure, but the prognostic role of MPO in stable patients with known atherosclerotic burden is unclear. METHODS: We examined plasma MPO concentrations and their relationship with prevalent significant coronary artery disease (defined as >50% stenosis in any coronary vessel) and incident major adverse cardiovascular events (MACEs), including death, myocardial infarction, and stroke, in a 3-year prospective follow-up study of 1895 patients undergoing elective coronary angiography. RESULTS: The median plasma MPO concentration was 101 pmol/L (interquartile range 68-187 pmol/L). Patients with plasma MPO concentrations >322 pmol/L (14.6% of population) had increased risk of developing future MACEs [hazard ratio (HR) 1.78, 95% CI 1.33-2.37, P < 0.001], and MPO as a single variable predictor of MACE showed an area under the ROC curve of 0.67. After adjusting for traditional cardiac risk factors, creatinine clearance, B-type natriuretic peptide, and high-sensitivity C-reactive protein (hsCRP), increased MPO concentrations remained significantly associated with incident MACEs over the ensuing 3-year period (HR 1.71; 95% CI 1.27-2.30, P < 0.001). In patients with increased hsCRP, MPO ≤322 pmol/L was associated with lower event rates than observed with MPO >322 pmol/L. CONCLUSIONS: Plasma MPO concentrations provide independent prognostic value for the prediction of long-term incident MACEs in a stable, medically managed patient population with coronary artery disease. In individuals with increased hsCRP concentrations, we observed lower risk of incident MACEs when concomitant MPO concentrations were low vs when MPO concentrations were high.
Authors: Nathan D Wong; Heidi Gransar; Jagat Narula; Leslee Shaw; Johanna H Moon; Romalisa Miranda-Peats; Alan Rozanski; Sean W Hayes; Louise E J Thomson; John D Friedman; Daniel S Berman Journal: JACC Cardiovasc Imaging Date: 2009-09
Authors: W H Wilson Tang; Ronit Katz; Marie-Luise Brennan; Ronnier J Aviles; Russell P Tracy; Bruce M Psaty; Stanley L Hazen Journal: Am J Cardiol Date: 2009-03-13 Impact factor: 2.778
Authors: W H Wilson Tang; Yuping Wu; Jaana Hartiala; Yiying Fan; Alexandre F R Stewart; Robert Roberts; Ruth McPherson; Paul L Fox; Hooman Allayee; Stanley L Hazen Journal: Arterioscler Thromb Vasc Biol Date: 2011-11-10 Impact factor: 8.311
Authors: Christine H J Kim; James B Mitchell; Christina A Bursill; Anastasia L Sowers; Angela Thetford; John A Cook; David M van Reyk; Michael J Davies Journal: Atherosclerosis Date: 2015-03-16 Impact factor: 5.162
Authors: Alexander P Reiner; Jaana Hartiala; Tanja Zeller; Joshua C Bis; Josée Dupuis; Myriam Fornage; Jens Baumert; Marcus E Kleber; Philipp S Wild; Stephan Baldus; Suzette J Bielinski; João D Fontes; Thomas Illig; Brendan J Keating; Leslie A Lange; Francisco Ojeda; Martina Müller-Nurasyid; Thomas F Munzel; Bruce M Psaty; Kenneth Rice; Jerome I Rotter; Renate B Schnabel; W H Wilson Tang; Barbara Thorand; Jeanette Erdmann; David R Jacobs; James G Wilson; Wolfgang Koenig; Russell P Tracy; Stefan Blankenberg; Winfried März; Myron D Gross; Emelia J Benjamin; Stanley L Hazen; Hooman Allayee Journal: Hum Mol Genet Date: 2013-04-24 Impact factor: 6.150
Authors: Muhammad Hammadah; Marie-Luise Brennan; Yuping Wu; Stanley L Hazen; W H Wilson Tang Journal: Am J Cardiol Date: 2016-01-28 Impact factor: 2.778
Authors: Michael Schivo; Timothy E Albertson; Angela Haczku; Nicholas J Kenyon; Amir A Zeki; Brooks T Kuhn; Samuel Louie; Mark V Avdalovic Journal: J Investig Med Date: 2017-03-03 Impact factor: 2.895
Authors: Christina Charles-Schoeman; Yuen Yin Lee; Ani Shahbazian; Xiaoyan Wang; David Elashoff; Jeffrey R Curtis; Iris Navarro-Millán; Shuo Yang; Lang Chen; Stacey S Cofield; Larry W Moreland; Harold Paulus; James O'Dell; Joan Bathon; S Louis Bridges; Srinivasa T Reddy Journal: Arthritis Rheumatol Date: 2017-01 Impact factor: 15.483
Authors: Cornelia Then; Christian Herder; Holger Then; Barbara Thorand; Cornelia Huth; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Andreas Lechner; Jürgen Scherberich; Jochen Seissler Journal: Clin Kidney J Date: 2020-09-06